UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

The journal of clinical endocrinology and metabolism, 2016-08, Vol.101 (8), p.3163-3170

2016

Volltextzugriff (PDF)

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

Osteoporosis international, 2015-02, Vol.26 (2), p.699-712

2015

Volltextzugriff (PDF)

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Osteoporosis international, 2019-01, Vol.30 (1), p.71-78

2019

Volltextzugriff (PDF)

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

Bone (New York, N.Y.), 2010-07, Vol.47 (1), p.131-139

2010

Volltextzugriff (PDF)

Mutations of the GNAS1 Gene, Stromal Cell Dysfunction, and Osteomalacic Changes in Non–McCune–Albright Fibrous Dysplasia of Bone

Journal of bone and mineral research, 2000-01, Vol.15 (1), p.120-128

2000

Volltextzugriff (PDF)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

Osteoporosis international, 2019-12, Vol.30 (12), p.2437-2448

2019

Volltextzugriff (PDF)

Short-Term Inhibition of Parathyroid Hormone Secretion by a Calcium-Receptor Agonist in Patients with Primary Hyperparathyroidism

The New England journal of medicine, 1997-11, Vol.337 (21), p.1506-1511

1997

Volltextzugriff (PDF)

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

Osteoporosis international, 2010-05, Vol.21 (5), p.837-846

2010

Volltextzugriff (PDF)

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Osteoporosis international, 2015-12, Vol.26 (12), p.2773-2783

2015

Volltextzugriff (PDF)

Alendronate and estrogen effects in postmenopausal women with low bone mineral density

The journal of clinical endocrinology and metabolism, 2000-02, Vol.85 (2), p.720-726

2000

Volltextzugriff (PDF)

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates

Osteoporosis international, 2020, Vol.31 (1), p.181-191

2020

Volltextzugriff (PDF)

Interleukin-6 : A potential mediator of the massive osteolysis in patients with Gorham-Stout disease

The journal of clinical endocrinology and metabolism, 1996-05, Vol.81 (5), p.1893-1897

1996

Volltextzugriff (PDF)

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

Osteoporosis international, 2017-10, Vol.28 (10), p.2967-2973

2017

Volltextzugriff (PDF)

S3 guideline sepsis-prevention, diagnosis, treatment, and aftercare : Summary of the strong recommendations

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2020-04, Vol.115 (3), p.178-188

2020

Volltextzugriff (PDF)

Dose-response relationships for alendronate treatment in osteoporotic elderly women

The journal of clinical endocrinology and metabolism, 1997, Vol.82 (1), p.265-274

1997

Volltextzugriff (PDF)

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

Osteoporosis international, 2014-07, Vol.25 (7), p.1953-1961

2014

Volltextzugriff (PDF)

Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep

Critical care medicine, 2001-09, Vol.29 (9), p.1756-1760

2001

Volltextzugriff (PDF)

Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation

Osteoporosis international, 2017-05, Vol.28 (5), p.1745-1752

2017

Volltextzugriff (PDF)

Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: Patient description and effects on the SF-36 health survey

Surgery, 2000-12, Vol.128 (6), p.1013-1021

2000

Volltextzugriff (PDF)

Terlipressin in patients with septic shock: friend or foe?

Intensive care medicine, 2004-05, Vol.30 (5), p.992; author reply 993-992

2004

Volltextzugriff (PDF)

Therapeutic controversies in primary hyperparathyroidism

The journal of clinical endocrinology and metabolism, 1999-07, Vol.84 (7), p.2275-2282

1999

Volltextzugriff (PDF)

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

Osteoporosis international, 2012-01, Vol.23 (1), p.233-245

2012

Volltextzugriff (PDF)

Weekly administration of alendronate: Rationale and plan for clinical assessment

Clinical therapeutics, 2000, Vol.22 (1), p.15-28

2000

Volltextzugriff (PDF)

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

The New England journal of medicine, 2004-03, Vol.350 (12), p.1189-1199

2004

Volltextzugriff (PDF)

Sedation assessment in critically ill patients with bispectral index

European journal of anaesthesiology, 2002, Vol.19 (1), p.18-22

2002

Volltextzugriff (PDF)

1 – 25 von 528

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(443)
Mit Volltextzugriff
(438)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(301)
Life Sciences & Biomedicine
(284)
Humans
(234)
Female
(155)
Biological And Medical Sciences
(136)
Medical Sciences
(122)
Male
(110)
Middle Aged
(107)
General & Internal Medicine
(95)
Aged
(88)
Adult
(79)
Animals
(65)
Endocrinology & Metabolism
(56)
Critical Care Medicine
(54)
Pharmacology. Drug Treatments
(36)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(31)
Double-Blind Method
(31)
Adolescent
(29)
Orthopedics
(29)
Oncology
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

Mutations of the GNAS1 Gene, Stromal Cell Dysfunction, and Osteomalacic Changes in Non–McCune–Albright Fibrous Dysplasia of Bone

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

Short-Term Inhibition of Parathyroid Hormone Secretion by a Calcium-Receptor Agonist in Patients with Primary Hyperparathyroidism

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Alendronate and estrogen effects in postmenopausal women with low bone mineral density

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates

Interleukin-6 : A potential mediator of the massive osteolysis in patients with Gorham-Stout disease

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

S3 guideline sepsis-prevention, diagnosis, treatment, and aftercare : Summary of the strong recommendations

Dose-response relationships for alendronate treatment in osteoporotic elderly women

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep

Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation

Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: Patient description and effects on the SF-36 health survey

Terlipressin in patients with septic shock: friend or foe?

Therapeutic controversies in primary hyperparathyroidism

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

Weekly administration of alendronate: Rationale and plan for clinical assessment

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

Sedation assessment in critically ill patients with bispectral index

Suchergebnisse filtern